Long-term combination chemotherapy using eribulin and trastuzumab for three patients with human epidermal growth factor receptor 2-positive metastatic breast cancer-Reference-Cited by-同舟云学术

Long-term combination chemotherapy using eribulin and trastuzumab for three patients with human epidermal growth factor receptor 2-positive metastatic breast cancer

Published:2016-06-21 Issue:4 Volume:5 Page:178-182
ISSN:2192-3183
Container-title:International Cancer Conference Journal
language:en
Short-container-title:Int Canc Conf J

Author:

Saeki Toshiaki,Araki Kazuhiro,Shimada Ken,Shigekawa Takashi,Nakayama Hirofumi,Segawa Yoshihiko,Mukai Hirofumi

Funder

Eisai

Publisher

Springer Science and Business Media LLC

Subject

General Earth and Planetary Sciences,General Environmental Science

Link

http://link.springer.com/content/pdf/10.1007/s13691-016-0253-y.pdf

Reference20 articles.

1. Mukai H, Saeki T, Shimada K et al (2015) Phase 1 combination study of Eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer. Invest New Drugs 33:119–127

2. Wilks S, Puhalla S, O’Shaughnessy J et al (2014) Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer. Clin Breast Cancer 14:405–412

3. Carlson RW, Allred DC, Anderson BO et al (2011) Invasive breast cancer. J Natl Compr Canc Netw 9:136–222

4. Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792

5. Gori S, Colozza M, Mosconi AM et al (2004) Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer. Br J Cancer 90:36–40

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antineoplastics;Reactions Weekly;2017-01